Prot# 021FSGS16010:A Randomized, Multicenter, Double-Blind, Parallel, Active-Control Study Of The Effects Of Sparsentan, A Dual Endothelin Receptor And Angiotensin Receptor Blocker, On Renal Outcomes In Patients With Primary Focal Segmental Glomeruloscler

Project: Research project

Project Details

StatusActive
Effective start/end date7/6/187/6/21

Funding

  • Quintiles, Inc. (Prot# 021FSGS16010)
  • Retrophin, Inc. (Prot# 021FSGS16010)